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The endothelial glycocalyx is a vital regulator of vascular protein permeability and hydraulic 
conductivity. Damage to this delicate layer can result in increased protein and water transit. The 
clinical importance of albuminuria as a predictor of kidney disease progression and vascular disease 
has driven research in this area. In this review we outline how research to date has attempted to 
measure the contribution of the endothelial glycocalyx to vessel wall permeability. We discuss the 
contrasting published results, comparing evidence for the role of the endothelial glycocalyx in 
regulating permeability in discrete areas of the vasculature and highlight the inherent limitations of 
the data that has been produced to date. In particular we draw the readers attention to the difficulties 
in interpreting a normal urinary albumin level in early disease models. In addition, we summarise the 
research supporting the view that glycocalyx damage is a key pathological step in a diverse array of 
clinical conditions including diabetic complications, sepsis, preeclampsia and atherosclerosis. 
Finally, we discuss novel methodologies including an ex vivo glomerular permeability assay that 




Water and solute exchange across the walls of the microcirculation are dynamic processes that are 
fundamental to tissue homeostasis. The net rates of exchange are regulated by alterations in systemic blood 
pressure (hydrostatic pressure), vessel density and size (vessel surface area), flow rate and concentration 
gradients, and the inherent permeability of the vessel walls. The basic structure of the capillary wall is 
conserved throughout the body, consisting of an endothelial cell monolayer, basement membrane and 
supporting cells. However, a high level of specialisation occurs within discrete areas of the vasculature, 
optimising the structure for the individual demands placed upon it. The endothelial glycocalyx layer on the 
luminal surface of the endothelial cells contributes to the permeability barrier formed by the vessel wall.1,2 
Glycocalyx literally translates from the Greek for ‘sugar coat’ glykys = sweet, kalyx = husk. This adherent 
structure includes proteoglycans, glycoproteins and glycolipids (figure 1).1,3-5 Proteoglycans consist of core 
proteins (e.g. syndecans and glypicans) with covalently-bound glycosaminoglycan side chains (e.g. heparan 
sulphate (HS) and chondroitin sulphate). The glycocalyx is not uniform across its depth.6 The two-layer fibre-
matrix model suggests a dense 200-300nm mesh-like inner layer, rich in proteoglycans covalently bound to 
the endothelial cell membrane and adherent glycosaminoglycans including long chains of hyaluronan (HA), 
and an outer more porous gel-like layer up to 1µm thick including adsorbed plasma proteins.6,7 Here we review 
the evidence for the importance of the endothelial glycocalyx as a regulator of endothelial and vascular 
permeability whilst noting the inherent difficulties in studying it. We then discuss the human diseases where 
glycocalyx damage and associated permeability alterations appear to be key pathogenic steps. 
 
The complexities of studying the endothelial glycocalyx as a permeability barrier 
Endothelial cells in vitro produce a surface glycocalyx providing an accessible model to study glycocalyx 
functions including shear stress sensing2 and permeability regulation.4 However it is much thinner than the 
glycocalyx seen in vivo limiting the applicability of in vitro research.4,8,9 As a result the majority of work studying 
the permeability of the glycocalyx has been conducted in vivo.  
 
Much research to date has focussed on the glomerular endothelial glycocalyx. This may be driven by our 
appreciation of the clinical importance of albuminuria and the ease with which urinary albumin creatinine ratios 
(uACR) can be quantified to provide a measure of albumin permeability across the glomerular filtration barrier 
(GFB) (figure 1). Early models of the GFB overestimated the contribution of the slit diaphragm to the restriction 
of albumin filtration.10 Recent models of the GFB, however, suggest that the glycocalyx represents a significant 
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protein barrier.11 This concurs with accumulating experimental evidence,12 indicating that the remaining 
components of the GFB, including the endothelial glycocalyx, provide the major barrier to protein permeability 
(figure 1).4,13-15 These estimates, combined with our increased understanding of cellular crosstalk within the 
GFB should make us question assumptions about the pathogenesis of albuminuria in multiple historical 
models.16,17 Albuminuria is the net result of albumin passage across the GFB (influenced by permeability), and 
albumin reabsorption and metabolism within the renal tubules. However, despite the widespread use of uACR, 
there is increasing evidence in rodent models that the uACR is not a sensitive test for changes in GFB 
permeability and hence not an ideal index of glycocalyx integrity: Using in vivo multiphoton microscopy in mice 
(figure 2) we have demonstrated that glomerular albumin leakage can be significantly increased before 
detectable levels of albumin appear in the urine.2 Other groups have reported similar data, demonstrating 
increased glomerular albumin leakage but no significant change in uACR.18 We hypothesise that this 
discrepancy is explained by tubular re-absorption of filtered albumin, resulting in a threshold effect whereby 
increased glomerular albumin permeability will not result in uACR increases until mechanisms of uptake and 
metabolism are overwhelmed. The role of tubular albumin uptake in humans is debated, but diseases resulting 
in tubular dysfunction, such as Fanconi syndrome and Dent’s disease do result in significant albuminuria.19 
Historical studies in diabetic patients using lysine to inhibit tubular albumin re-absorption similarly indicate that 
tubular albumin uptake may influence uACR results.20 In summary the clinical importance of albuminuria is 
now well established, but the absence of albuminuria in early rodent models of disease does not exclude 
increased albumin passage across the GFB. 
 
Relatively little research has been conducted studying glycocalyx-dependant permeability changes in the 
systemic vasculature. In part this is due to the complex methods needed to study glycocalyx specific changes. 
We have previously studied mesenteric micro-vessels in real time using confocal microscopy, but due to the 
fragility of the glycocalyx layer careful tissue preparation is needed.1 Work comparing the depth of the 
endothelial glycocalyx within the continuous capillaries of the systemic and pulmonary vasculature highlighted 
dramatic variability in glycocalyx depth.21 To date little is known about whether the composition of the 
glycocalyx varies between these sites. It seems likely that the glycocalyx within discrete areas of our 
vasculature is specialised, adapting to perform the combination of tasks needed at each tissue site optimally. 
Variability in the glycocalyx structure means that pathological insults may not affect all areas of the glycocalyx 
equally. Specialisation is also seen in the endothelial monolayer itself. The ‘double barrier’ concept was first 
introduced by Rehm et al and is illustrated in figure 3.22 They found in guinea pig hearts that simultaneous 
disruption of both the cellular barrier (using ischaemia or histamine) and glycocalyx damage (using heparinase) 
 
 5 
was needed to increase coronary vessel leakage.22 This work led to the hypothesis that glycocalyx damage 
overlying a tight cellular barrier will have minimal (direct) influence on monolayer or vessel wall permeability. 
In contrast, identical glycocalyx damage overlying a ‘leaky’ cellular monolayer will result in rapid measurable 
increases in vessel permeability. When studying glycocalyx-dependant permeability changes within the 
systemic vasculature it is therefore important to consider both how glycocalyx structural adaptations and the 
underlying endothelial cell phonotype will influence detectable permeability changes. 
 
To measure the contribution of the endothelial glycocalyx to vessel permeability comparisons have generally 
been made following a ‘glycocalyx insult’. Enzymatic removal or genetic knock down of a specific glycocalyx 
component is commonly used for this purpose. However, the method used can dramatically alter the results 
of such studies. Rapid removal of HS, using human heparanase or heparanase III, increased albumin passage 
across endothelial monolayers.4 However knock out of the HS proteoglycan syndecan 1 did not result in 
albuminuria in mice.23 In addition, mice lacking endothelial N-Deacetylase and N-Sulfotransferase (NDST-1), 
a key enzyme in modifying HS chains, did not become albuminuric.24 A similar pattern of results was seen in 
experiments targeting HA. Hyaluronidase has been shown to have a plasma half-life of approximately 3 
minutes before being taken up in the liver via a mannose-dependant mechanism.25 The short plasma half-life 
and the relatively high molecular weight (55-61kDa) of hyaluronidase result in a high level of glycocalyx-
degrading activity with limited ‘off target’ effects. Haraldsson et al found that removing HA from the endothelial 
glycocalyx using hyaluronidase increased glomerular albumin transit 5.6-fold, a figure consistent with our own 
findings.26-28 Tamoxifen induced endothelial specific knock down of hyaluronan synthase 2 (HAS2) also 
resulted in significant albuminuria from 4 weeks post induction, which persisted to 12 weeks (experimental end 
point). In contrast, Dane et al showed that 4 weeks hyaluronidase infusion did not result in measurable 
albuminuria although they did demonstrate increased glomerular albumin leakage in 90% of glomeuli.18 Whilst 
this work again highlights that albuminuria is a poor measure of low-level glomerular albumin leakage, it also 
suggests that the differences in time-scale, as well as the precise component targeted may influence 
glycocalyx permeability changes. Knockdown in genetic models may have resulted in compensatory 
adaptations e.g. up-regulation of other glycocalyx components. In contrast the rapid enzymatic removal of 
glycocalyx components may prevent adaptations from occurring before functional assessments are made.24,26-
29 In addition, the rapid removal of a single structural component of the glycocalyx may leave the structure as 
a whole vulnerable to further non-specific destruction by the shear forces applied by the circulation. Another 
contrast between enzymatic removal and genetic knock down of a glycocalyx component is the generation of 
circulating glycocalyx fragments. The enzymatic release of fragments is also non-specific. Heparanase 
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increased syndecan 1 and 4 loss from the glycocalyx structure, possibly by exposing cleavage sites for the 
actions of other circulating enzymes.30 The influence of active signalling fragments released following 
glycocalyx enzymatic degradation on vessel permeability has not been directly investigated, but they represent 
a potentially important pharmacological target.31,32  
 
In summary, when studying the glycocalyx careful consideration needs to be given to the chosen methodology 
and tissue. Whilst the glomerular endothelial glycocalyx lends itself to studying permeability the uACR should 
be interpreted with caution. Measures of systemic permeability need to be considered in context. A ‘double 
barrier’ can exist and in the absence of specific manipulations, the relative contributions of the components 
are difficult to establish. With the development of more sensitive and specific methods to assess permeability 
we expect our understanding of the role of individual glycocalyx components to rapidly increase in the next 
decade.33 
 
The relevance of glycocalyx permeability changes in disease 
Diabetes  
There is evidence that the diabetic milieu affects the vasculature globally. Nieuwdorp et al measured the total 
glycocalyx volume by comparing the volume of distribution of erythrocytes and dextran 40 in healthy 
volunteers. They found that 6 hours of hyperglycaemia reduced the glycocalyx volume to 50% of the baseline 
value.34 More recently an intervention study has shown that improved glycaemic control in type 2 diabetic 
patients (for 12 months) results in a significant increase in glycocalyx depth. Glycocalyx depth in this study 
was measured using side-stream dark field imaging (SDF) to assess the perfused boundary region depth (a 
measure inversely proportional to glycocalyx thickness) on sublingual vessels. This suggests that systemic 
glycocalyx damage in early diabetes is at least partially reversible.35 We have found that changes to the 
endothelial glycocalyx occur early in the disease course, suggesting that they could represent a valuable direct 
therapeutic target.33 Using electron microscopy on glomerular capillaries we have shown that the percentage 
surface covered by the glycocalyx is one of the earliest detectable vascular changes in diabetes.33 Consistent 
with this Targosz-Korecka et al used atomic force microscopy to ‘map’ the glycocalyx on diabetic db/db 
mouse aortas.36 They found that endothelial glycocalyx coverage was significantly reduced by week 11.36 
At this time point significant depth reductions in the glycocalyx structure were not detected.36 Although 
glycocalyx damage occurs early in diabetic disease, the clinical manifestations of this damage may be 




Diabetic nephropathy (DN) 
The hallmark of DN is micro-albuminuria. In diabetes the uACR is a key screening test, predicting patients at 
the highest risk of progressive renal and vascular disease.37 Using electron microscopy to study glomerular 
structural changes in diabetic patients, loss of endothelial fenestration area was found to correlate with the 
uACR more strongly than podocyte detachment.38 These data suggest that endothelial damage is likely to be 
one of the key steps that results in albuminuria in diabetes.38 The authors of this study did not examine the 
glycocalyx, but it seems likely that the endothelial cell damage, resulting in fenestration loss, was the result of 
altered vascular endothelial growth factor (VEGF) signalling.39,40 We have shown that altered VEGF signalling 
results in glycocalyx loss.15,28,41 Given the evidence supporting the importance of the glycocalyx to glomerular 
filtration, it seems likely that glycocalyx damage contributed to the micro-albuminuria seen in these patients. 
 
Experimental evidence supports this view. On cultured monolayers of conditionally immortalised glomerular 
endothelial cells (GEnC) we have shown that high concentrations of glucose result in a marked reduction in 
the biosynthesis of the glycocalyx component HS with an associated increase in albumin permeability.42 
Jeansson et al confirmed that increased glomerular albumin leakage contributed to the albuminuria detected 
in animal models of diabetes by cooling isolated kidneys to 8°C to limit tubular effects.43 Loss of HA and HS 
from the glomerular capillary wall has been confirmed in streptozocin (STZ) induced diabetic rats and Zucker 
fatty rats suggesting that glycocalyx damage is likely to contribute to the increase in albumin filtration seen in 
these disease models.44,45 Using high power electron microscopy we have shown in rodent diabetic models 
that glomerular endothelial glycocalyx changes occur before any alterations to the other components of the 
filtration barrier.28,33 At this early time point, using an isolated glomerular albumin permeability assay, we have 
confirmed that glomerular glycocalyx loss is associated with increased glomerular albumin permeability in the 
STZ diabetic model.28 This unique assay has the advantage of studying glomerular permeability in the absence 
of haemodynamic influence, ensuring that alterations in the glomerular perfusion pressure will not influence 
permeability measurements. In addition, this assay allows us to study changes in glomerular permeability in 
isolation from the renal tubules. As discussed, we feel this is important in early disease models with low-level 
albuminuria. Using this assay, we found that glomerular albumin leakage may be significantly increased before 
a rise in uACR is detectable. In summary, the current evidence suggests that glycocalyx injury is likely to be 
contributory to the early pathogenesis of DN. 
 
Diabetic retinopathy (DR) 
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Diabetic retinopathy, like DN, is a manifestation of diabetic microvascular damage. The retina is a continuation 
of the central nervous system with a blood retina barrier. The pathogenesis of DR has been reviewed in detail 
elsewhere,46,47 but the role of the retinal endothelial glycocalyx, and its impairment in diabetes, is an area of 
on going research. DR is characterised by micro-aneurysms, leukocyte-endothelial adhesion, haemorrhage, 
capillary occlusion, neovascularisation and increased permeability.48 Diabetic rats have a significantly thinner 
retinal endothelial glycocalyx compared to control rats (28.3nM vs. 60.2nM p<0.01), measured using 
transmission electron microscopy.49 In addition, in the Akita mouse model of type 1 diabetes, anaesthetised 
diabetic mice have a significantly thinner glycocalyx in retinal arterioles.48 In human volunteers, combined 
fluorescein/indocyanine green angiography also demonstrated a significantly thinner glycocalyx in patients 
with type 2 diabetes compared to healthy controls.50 In the same study the authors measured the rate at which 
125I-labelled albumin left the plasma, confirming an increased rate of loss in diabetic patients – consistent with 
an increase in systemic albumin permeability.50 Although a reduction in tight junctions within the inter-
endothelial cleft of retinal vessels has also been reported early in diabetic disease, it seems likely that 
glycocalyx damage contributes to microvascular permeability changes in DR.51 
 
Sepsis 
During sepsis the endothelial glycocalyx becomes thinner and the cover more sparse, contributing to tissue 
oedema.52,53 In mice, intravenous lipopolysaccharide (LPS) injection results in activation of the innate 
immune system, shock, lactic acidosis, myocardial impairment and increased levels of circulating tumour 
necrosis factor alpha (TNF) and interleukin-6 (IL-6).54 Following LPS administration mice have significantly 
thinner aortic glycocalyx compared to controls.55 Elevated levels of TNF are likely to contribute to 
glycocalyx damage in this model via increased matrix metalloprotease activity and syndecan loss.56 In 
human volunteers a low-dose endotoxin model resulted in a significant reduction in the depth of the 
sublingual vessel glycocalyx (measured using side stream imaging) and a concurrent elevation in plasma 
hyaluronan, suggesting glycocalyx shedding.57 Multiple biomarkers of glycocalyx shedding have been 
studied in humans as markers of sepsis including syndecan 1, HS and HA.52,58,59 It is hoped that in the future 
these targets may provide clinicians with additional diagnostic and prognostic information. In sepsis 
circulating sheddases including A disintegrin and metalloproteinase 15 (ADAM15), heparanase, and matrix 
metalloprotease (MMP) 2 and 9 have been implicated in the degradation of the glycocalyx.59-62 It seems 
likely therefore that the albuminuria observed in sepsis results from glycocalyx injury and hence increased 




Increased pulmonary vascular permeability in sepsis manifests as acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS), both can occur early in sepsis.66 However, the evidence to date suggests that we 
should not extrapolate evidence supporting peripheral glycocalyx damage mediating increased vasculature 
permeability to the pulmonary vasculature in sepsis. Mouse pulmonary endothelial glycocalyx appears to be 
substantially thicker than that seen in the mouse systemic vessels (cremaster muscle).67 Conflicting evidence 
exists supporting the role of the pulmonary vessel glycocalyx as a permeability barrier. Whilst a study using 
bovine lung microvasculature endothelial cells in vitro suggested that HS within the glycocalyx contributed to 
cell’s barrier function, a study using ex vivo rat lungs did not.68,69 In addition, in isolated mouse lungs perfused 
with 4% Evans blue labelled albumin, neither water nor albumin permeability was measurably altered by 
glycocalyx degradation. In vivo heparinase-III enzyme infusion did not result in detectable pulmonary oedema 
in mice.70 These findings could be explained by the double barrier hypothesis (figure 3). Glycocalyx injury in 
isolation may not result in measurable increases in pulmonary permeability to macromolecules in the presence 
of an intact second barrier (the endothelial monolayer). However, by altering the level of immune cell 
extravasation and inflammation, the pulmonary glycocalyx may still have a key role in maintaining pulmonary 
homeostasis.70 
 
The endothelial cells within the cerebral circulation form part of the blood brain barrier, limiting transcytosis 
and solute diffusion.71 The glycocalyx forms the most luminal layer of the blood brain barrier. Whilst cytokines 
smaller than 40kDa are likely to freely cross the glycocalyx, the passage of larger molecules and interactions 
between circulating cells and the endothelium are restricted by an intact glycocalyx.71,72 Groups are currently 
working to investigate the function and structure of the cerebral glycocalyx.72,73 In vivo imaging in mice 
suggests that the cerebral arteries and capillaries have an intact glycocalyx, whilst veins and venules do not.72 
As yet we do not know if the same distribution will be seen in the human cerebral circulation. During sepsis 
patients commonly develop cognitive impairment (acute delirium). The pathogenesis of this condition is 
complex with evidence to date suggesting a role for cytokines  (IL-1, IL-6 and TNF) penetrating the blood 
brain barrier and activating astrocytes.74 Work by Hippensteel et al now suggests that during sepsis HS 
fragments penetrate the hippocampal blood brain barrier to inhibit long-term potentiation – the process 
responsible for memory formation.32,75 The blood brain barrier of the hippocampal region appears to be 
susceptible to damage with an apparent predisposition to age related vascular dysfunction.76 It seems possible 
therefore that an increase in the permeability of the blood brain barrier of the hippocampus to HS fragments, 
possibly as a direct result of the sepsis-induced glycocalyx shedding, contributed to the hippocampal HS 
fragment accumilation.32 Interestingly a limited clinical study using SDF imaging has shown that the glycocalyx 
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depth varies between cortical and hippocampal micro-vessels.73 The hippocampal endothelial glycocalyx was 
found to be thicker than the cortical endothelial glycocalyx, suggesting that structural differences in the 
glycocalyx at the two sites may exit.73 Further work is needed to determine whether the hippocampal 
microvascular glycocalyx is predisposed to damage during sepsis as this could represent an exciting 
therapeutic target in the future to limit the comorbidity associated with sepsis. 
 
Pre-eclampsia  
Pre-eclampsia (PE) is a complication affecting 3-5% of pregnancies. The hallmark of the condition is 
endothelial cell damage; leading to altered microvascular permeability.77,78 Endothelial glycocalyx dysfunction 
may contribute to this. Activation and dysfunction of the maternal endothelium in PE is mediated (in part) 
through the release of placentally derived factors.79 Hypoxic trophoblasts release anti-angiogenic cytokines 
including soluble fms-like tyrosine kinase-1 (sFlt-1) into the maternal circulation. In addition there is a reduction 
in the pro-angiogenic placental growth factor (PlGF) – a member of the VEGF family.80 The resulting imbalance 
contributes to the altered vascular permeability seen in PE.81 Historically we have shown that VEGF-A, VEGF-
C and VEGF-A165b alter the endothelial glycocalyx.15,41 Interestingly a failure in first trimester up-regulation of 
VEGF-A165b has been shown to be predictive for the development of PE.82 The important link between VEGF, 
permeability and the endothelial glycocalyx is an increasing focus in PE research.  
 
The net effect of PE is glycocalyx degradation illustrated by an increased perfused boundary region in 
sublingual capillaries assessed by side stream imaging in patients with early onset PE.83 However the 
mechanism of damage remains unclear due to conflicting data to date. HS and HA are both elevated in early-
onset PE (onset before 34 weeks’), severe PE and the related syndrome of haemolysis, elevated liver enzymes 
and low-platelets (HELLP).83-85 However whilst soluble syndecan-1 has been shown to increase with 
advancing gestation in both normal pregnancy and in PE, its utility as a marker of PE remains unclear. 83,86,87 
The sample size, diagnostic criteria and different PE sub-types may explain the discrepancies observed. We 
have recently developed electron microscopy based methodologies to reliably measure the glycocalyx depth 
in both the foetal and maternal circulation of human placental tissue to aid future work in this area.88  
 
Atherosclerosis 
The major focus of this review has been on the function of the endothelial glycocalyx within the 
microvasculature. However, there is now an emerging field of research studying the role of the glycocalyx in 
the prevention of atherosclerosis in larger blood vessels. Atherosclerosis is a chronic arterial vascular disease 
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resulting from lipid-filled plaque accumulation.89 The subsequent erosion or rupture of plaques can result in 
acute arterial occlusion, myocardial infarction or cerebrovascular accident. Damage to the endothelial 
glycocalyx has been linked to the pathogenesis of atheroma through multiple pathways, which have recently 
been reviewed by Mitra et al, but alterations in trans-endothelial permeability appear to be a key step.89 
Atheroma tends to form in areas of non-laminar blood flow adjacent to bends or branch points.89,90 In vitro, 
non-uniform fluid flow rapidly results in reduced glycocalyx expression of HS and sialic acids, with an 
associated reduction in glycocalyx thickness and coverage.89 Areas of glycocalyx damage correlated with 
oxidised low-density lipoprotein (LDL) cholesterol uptake.89 In vivo, lipid accumulation in apolipoprotein E-
deficient (ApoE -/-) mice has been shown to increase in areas of endothelium with incomplete glycocalyx cover 
(71% glycocalyx cover in regions of plaque vs. 97% cover in plaque free regions)91 LDL cholesterol uptake is 
considered is important because it triggers cluster of differentiation 40 (CD40/CD40 ligand (L)) signalling 
pathways and subsequent macrophage uptake and degradation of oxidised LDL results in their transformation 
into foam cells, a key finding on histological examination of plaques.92 
 
Conclusions 
Further research into the structural variability of the glycocalyx and the contribution of the endothelial 
glycocalyx to vessel wall permeability is needed. This research needs to be targeted to both the organ and 
vessel of interest. The glycocalyx is a highly specialised structure and pathological states should not be 
expected to affect remote vascular beds, or the different vessels within them in the same way. Highly sensitive 
tools like the ex vivo glomerular permeability assay are providing new evidence that glycocalyx injury in early 
disease models has functional consequences and should not be ignored. Glycocalyx damage is associated 
with increased vessel wall permeability in multiple clinical conditions and has massive potential medical 
relevance. Restoring or maintaining the glycocalyx represents an inviting therapeutic strategy, but for the full 
potential of this strategy to be realised we need to gain an increased understanding of how the glycocalyx 




















Figure 1. The glomerular filtration barrier The GFB consists of glomerular endothelial cells (GEnC), 
the glomerular basement membrane and podocytes.93,94 GEnC possess numerous transcellular fenestrations, 
which permit the high hydraulic permeability necessary for filtration, and a glycocalyx which covers the luminal 
surface, extending over the fenestrations. Podocytes form a second cellular layer by interdigitating their foot 
processes, which connect at the slit diaphragms. The glycocalyx is a complex structure containing core 
proteoglycans such as syndecans and glipicans holding glycosaminoglycans (GAGs) heparan sulphate (HS), 
chondroitin sulphate (CS) and hyaluronan (HA) to the cell surface. The glycocalyx contributes to the filtration 
barrier by depleting the filtrated protein concentration before it reaches the fenestrated glomerular endothelial 
cell surface. The generation of a zone of protein-depleted filtrate adjacent to the luminal membrane of 
endothelial cells (shown in pink) limits loss of macromolecules from the plasma and reduces the effective 






Figure 2. A live perfused mouse glomerulus imaged under anaesthesia using 
multiphoton microscopy. Image taken 10 minutes after an intravenous bolus of FITC-wheat germ 
agglutinin (WGA). This lectin binds to sialic acid residues within the glycocalyx (labelled green). The plasma 
within the capillary loops was labelled red with AlexaFlour-conjugated albumin. The dark areas within the 
capillary loops represent circulating blood cells. The glomerular endothelial glycocalyx is a continuous layer 
within the glomerular capillaries contributing to the restriction of macromolecule and water leakage from the 
glomerulus into the Bowman’s space (Bar = 50μm.) Unpublished image M Butler* Supported NIH grant S10 
OD021833 to the USC Multi-Photon Microscopy Core, and MRC grant MR/M018237/1 
 
Figure 3. The double barrier concept 
A. In health both the intact glycocalyx and a tight endothelial monolayer can limit vascular wall permeability to 
macromolecules (including albumin). B. When damage to the endothelial barrier is limited to the glycocalyx, in 
areas of the vasculature where a tight cellular monolayer exits, an intact second barrier remains. This tight 
endothelial monolayer continues to limit macromolecule transit. In such areas it is currently not possible to 
directly measure the contribution of the endothelial glycocalyx to the vessel wall permeability. C. When damage 
affects both the glycocalyx and the permeability of the underlying monolayer, marked increases in the vascular 
wall permeability will result, but calculating the relative contribution of the glycocalyx to the vessel wall 
permeability, again is not possible. In summary in order to directly measure the contribution of the glycocalyx 
to vessel permeability vessels lacking a tight endothelial monolayer must be selected until new techniques are 
developed that can measure macromolecule concentrations in the ‘sub-glycocalyx space’. 
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